Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors

por Rovithi, Maria, Gerritse, Sophie L., Honeywell, Richard J., ten Tije, Albert J., Ruijter, Rita, Peters, Godefridus J., Voortman, Jens, Labots, Mariette, Verheul, Henk M.W.
Publicado 2019

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors

por Gerritse, Sophie L., Labots, Mariette, Heine, Rob Ter, Dekker, Henk, Poel, Dennis, Tauriello, Daniele V. F., Nagtegaal, Iris D., Van Den Hombergh, Erik, Van Erp, Nielka, Verheul, Henk M. W.
Publicado 2022

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

por Verhoeff, Sarah R., Oosting, Sjoukje F., Elias, Sjoerd G., van Es, Suzanne C., Gerritse, Sophie L., Angus, Lindsay, Heskamp, Sandra, Desar, Ingrid M.E., Menke-van der Houven van Oordt, C. Willemien, van der Veldt, Astrid A.M., Arens, Anne I.J., Brouwers, Adrienne H., Eisses, Bertha, Mulders, Peter F.A., Hoekstra, Otto S., Zwezerijnen, Gerben J.C., van der Graaf, Winette T.A., Aarntzen, Erik H.J.G., Oyen, Wim J.G., van Herpen, Carla M.L.
Publicado 2023